SCHEDULE 13G
 
Amendment No. 0
LOXO ONCOLOGY INC
COMMON STOCK
Cusip #548862101
Check the appropriate box to designate the rule pursuant to which this 
Schedule is filed:
[x] 	  Rule 13d-1(b)
[ ] 	  Rule 13d-1(c)
[ ] 	  Rule 13d-1(d)
Cusip #548862101
Item 1: 	   	Reporting Person - FMR LLC
Item 2: 	   	(a)  	[ ]
   	   	(b)  	[ ]
Item 4: 	   	Delaware
Item 5: 	   	756,246
Item 6: 	   	0
Item 7: 	   	2,934,365
Item 8: 	   	0
Item 9: 	   	2,934,365
Item 11: 	   	14.999%
Item 12: 	   	HC
Cusip #548862101
Item 1: 	   	Reporting Person - Edward C. Johnson 3d
Item 2: 	   	(a)  	[ ]
   	   	(b)  	[ ]
Item 4: 	   	United States of America
Item 5: 	   	0
Item 6: 	   	0
Item 7: 	   	2,934,365
Item 8: 	   	0
Item 9: 	   	2,934,365
Item 11: 	   	14.999%
Item 12: 	   	IN
Cusip #548862101
Item 1: 	   	Reporting Person - Abigail P. Johnson
Item 2: 	   	(a)  	[ ]
   	   	(b)  	[ ]
Item 4: 	   	United States of America
Item 5: 	   	0
Item 6: 	   	0
Item 7: 	   	2,934,365
Item 8: 	   	0
Item 9: 	   	2,934,365
Item 11: 	   	14.999%
Item 12: 	   	IN
Cusip #548862101
Item 1: 	   	Reporting Person - Select Biotechnology Portfolio
Item 2: 	   	(a)  	[ ]
   	   	(b)  	[ ]
Item 4: 	   	Massachusetts
Item 5: 	   	1,611,362
Item 6: 	   	0
Item 7: 	   	0
Item 8: 	   	0
Item 9: 	   	1,611,362
Item 11: 	   	8.237%
Item 12: 	   	IV
 
Item 1(a). 	    	Name of Issuer:
 
  	  	          	LOXO ONCOLOGY INC
 
Item 1(b). 	    	Address of Issuer's Principal Executive Offices:
 
  	  	          	1 Landmark Square, Suite 1122
  	  	          	Stamford, CT 06901
  	  	          	USA
 
Item 2(a). 	     	 Name of Person Filing:
 
  	   	               	 FMR LLC
 
Item 2(b). 	     	 Address or Principal Business Office or, if None, 
Residence:
 
  	   	               	 245 Summer Street, Boston, Massachusetts 02210
 
Item 2(c). 	     	 Citizenship:
 
  	   	               	 Not applicable
 
Item 2(d). 	     	 Title of Class of Securities:
 
  	   	               	 COMMON STOCK
 
Item 2(e). 	     	 CUSIP Number:
 
  	   	               	 548862101
 
Item 3. 	    	This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) 
or (c) and the
person filing, FMR LLC, is a parent holding company in accordance with
Section 240.13d-1(b)(1)(ii)(G).   (Note:  See Exhibit A).
 
Item 4. 	    	Ownership
 
  	  	     	(a)    Amount Beneficially Owned: 	2,934,365
 
  	  	     	(b)    Percent of Class: 	14.999%
 
  	  	     	(c)    Number of shares as to which such person has:
 
  	  	     	       (i)    sole power to vote or to direct the vote: 	
756,246
 
  	  	     	       (ii)    shared power to vote or to direct the vote: 	0
 
  	  	     	       (iii)    sole power to dispose or to direct the 
disposition of: 	2,934,365
 
  	  	     	       (iv)    shared power to dispose or to direct the 
disposition of: 	0
 
Item 5. 	    	Ownership of Five Percent or Less of a Class.
 
  	    	     	Not applicable.
 
Item 6. 	    	Ownership of More than Five Percent on Behalf of Another 
Person.
 
  	 Various persons have the right to receive or the power to direct the 
receipt of dividends from, or the proceeds from the sale of, the COMMON 
STOCK of LOXO ONCOLOGY INC. No one other person's interest in the COMMON 
STOCK of LOXO ONCOLOGY INC is more than five percent of the total 
outstanding COMMON STOCK.
  	 
Item 7. 	    	Identification and Classification of the Subsidiary Which 
Acquired the Security Being Reported on By the Parent Holding Company.
 
  	    	     	See attached Exhibit A.
 
Item 8. 	    	Identification and Classification of Members of the Group.
 
  	    	     	Not applicable.
 
Item 9. 	    	Notice of Dissolution of Group.
 
  	    	  	Not applicable.
 
Item 10. 	    	Certifications.
 
  	    	     	

By signing below I certify that, to the best of my knowledge and belief, 
the securities referred to above were acquired and are held in the ordinary 
course of business and were not acquired and are not held for the purpose 
of or with the effect of changing or influencing the control of the issuer 
of the securities and were not acquired and are not held in connection with 
or as a participant in any transaction having that purpose or effect.

 
Signature
 
  	    	     	

After reasonable inquiry and to the best of my knowledge and belief, I 
certify that the information set forth in this statement is true, complete 
and correct.

  	December 9, 2015
  	Date
 
  	/s/ Marc R. Bryant
  	Signature
 
  	Marc R. Bryant
  	 Duly authorized under Power of Attorney effective as of September 23, 
2015, by and on behalf of FMR LLC and its direct and indirect subsidiaries*


* This power of attorney is incorporated herein by reference to Exhibit 24 
to the Form 4 filed by FMR LLC on November 25, 2015, accession number: 
0000315066-15-003312


Exhibit A
 

                 Pursuant to the instructions in Item 7 of Schedule 13G, 
the following table lists the identity and Item 3 classification, if 
applicable, of each relevant entity that beneficially owns shares of the 
security class being reported on this Schedule 13G.

 
Entity 	ITEM 3 Classification
FMR CO., INC * 	IA
FIDELITY INSTITUTIONAL ASSET MANAGEMENT TRUST COMPANY (formerly known as
         PYRAMIS GLOBAL ADVISORS TRUST COMPANY) 	BK
FIAM LLC (formerly known as PYRAMIS GLOBAL ADVISORS, LLC)   IA
  	 
  	 
* Entity beneficially owns 5% or greater of the outstanding shares of the 
security class being reported on this Schedule 13G.
 
 

                Edward C. Johnson 3d is a Director and the Chairman of FMR 
LLC and Abigail P. Johnson is a Director, the Vice Chairman, the Chief 
Executive Officer and the President of FMR LLC.

 

                Members of the family of Edward C. Johnson 3d, including 
Abigail P. Johnson, are the predominant owners, directly or through trusts, 
of Series B voting common shares of FMR LLC, representing 49% of the voting 
power of FMR LLC. The Johnson family group and all other Series B 
shareholders have entered into a shareholders' voting agreement under which 
all Series B voting common shares will be voted in accordance with the 
majority vote of Series B voting common shares. Accordingly, through their 
ownership of voting common shares and the execution of the shareholders' 
voting agreement, members of the Johnson family may be deemed, under the 
Investment Company Act of 1940, to form a controlling group with respect to 
FMR LLC.

 

                Neither FMR LLC nor Edward C. Johnson 3d nor Abigail P. 
Johnson has the sole power to vote or direct the voting of the shares owned 
directly by the various investment companies registered under the 
Investment Company Act ("Fidelity Funds") advised by Fidelity Management & 
Research Company ("FMR Co"), a wholly owned subsidiary of FMR LLC, which 
power resides with the Fidelity Funds' Boards of Trustees. Fidelity 
Management & Research Company carries out the voting of the shares under 
written guidelines established by the Fidelity Funds' Boards of Trustees.

 

                This filing reflects the securities beneficially owned, or 
that may be deemed to be beneficially owned, by FMR LLC, certain of its 
subsidiaries and affiliates, and other companies (collectively, the "FMR 
Reporters"). This filing does not reflect securities, if any, beneficially 
owned by certain other companies whose beneficial ownership of securities 
is disaggregated from that of the FMR Reporters in accordance with 
Securities and Exchange Commission Release No. 34-39538 (January 12, 1998).

 
RULE 13d-1(k)(1) AGREEMENT
 

                The undersigned persons, on December 9, 2015, agree and 
consent to the joint filing on their behalf of this Schedule 13G in 
connection with their beneficial ownership of the COMMON STOCK of LOXO 
ONCOLOGY INC at November 30, 2015.

 
  	FMR LLC
 
  	By /s/ Marc R. Bryant
  	Marc R. Bryant
  	Duly authorized under Power of Attorney effective as of September 23, 
2015, by and on behalf of FMR LLC and its direct and indirect subsidiaries*
 
  	Edward C. Johnson 3d
 
  	By /s/ Marc R. Bryant
  	Marc R. Bryant
  	Duly authorized under Power of Attorney effective as of October 12, 
2015, by and on behalf of Edward C. Johnson 3d*
 
  	Abigail P. Johnson
 
  	By /s/ Marc R. Bryant
  	Marc R. Bryant
  	Duly authorized under Power of Attorney effective as of October 12, 
2015, by and on behalf of Abigail P. Johnson*
 
  	Select Biotechnology Portfolio
 
  	By /s/ Marc R. Bryant
  	Marc R. Bryant
  	Secretary


* This power of attorney is incorporated herein by reference to Exhibit 24 
to the Form 4 filed by FMR LLC on November 25, 2015, accession number: 
0000315066-15-003312